Bipolar Disorder Clinical Trial
Official title:
An Open Label, Randomised, Valproate-Controlled Study to Evaluate the Efficiency and Safety of Quetiapine Fumarate in the Treatment of Acute Manic Patients With Bipolar Disorder.
This is an open label, randomised, parallel-group study to compare the efficacy and safety of
quetiapine and valproate used as monotherapy in the treatment of mania in patients
hospitalised for an acute manic episode. After given of informed consent and undergoing
screening procedures, the patients will be randomised into quetiapine or valproate group on
Day 1. The efficacy of study treatment on symptoms of mania will be assessed at Day 28.
Patients will not permitted to use any psychoactive or antipsychotic medications throughout
the study period other than those expressly permitted by the protocol.
At each centre, the same individual will administer a specific psychiatric assessment for a
patient at all study visits in order to reduce variability in rating scale scoring. Before
the initiation of the study, a consistency assessment will be done among the investigators
who conduct the scale assessment in each centre.
The rationale for using the quetiapine to treat patients with acute mania is multifold. A
potential major advantage for quetiapine is its demonstrated tolerability. Because of the low
incidence of EPS, quetiapine should be better tolerated than other antipsychotic medications
in this sensitive patient population. The limited potential for weight gain and prolactin
elevation may promote long-term treatment compliance.
The effect of quetiapine alone or adjunctive with mood stabilizers in the treatment of acute
mania in patients with bipolar disorder has been confirmed through 4 phase III clinical
trials (8,9). Based on the results of these clinical trials, the use of Seroquel in the acute
mania of bipolar disorder has been approved in US, UK and other major markets in Europe.
Quetiapine is also been recommended as alternative therapy for acute mania treatment in the
practice guideline (10). The present study is to assess the effectiveness of quetiapine and
valproate in the treatment of Chinese patients with acute mania over a treatment period of 4
weeks. Primary objective The primary objective of the study is to evaluate the effectiveness
of quetiapine fumarate used as monotherapy in the treatment of symptoms of acute mania in
patients with bipolar disorder, by evaluation of the change from baseline in YMRS total score
at Day 28 (LOCF).
Secondary objectives
The secondary objectives of the study are to evaluate the following:
- The effectiveness of quetiapine used as monotherapy to treat symptoms in patients with
acute mania by evaluation of YMRS/CGI response rate at Day 28 (LOCF)
- The effectiveness of quetiapine used as monotherapy to improve clinical status in
patients with acute mania by evaluation of change from baseline in CGI-S score at Day 28
(LOCF)
- The effectiveness of quetiapine used as monotherapy to treat depressive symptoms in
patients with acute mania by evaluation of change from baseline in MADRS total score at
Day 28 (LOCF)
- The effectiveness of quetiapine used as monotherapy to treat psychotic symptoms in
patients with acute mania by evaluation of change from baseline in PANSS total score at
Day 28 (LOCF)
- The safety and tolerability of quetiapine used as monotherapy to treat symptoms in
patients with acute mania
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05111548 -
Brain Stimulation and Cognitive Training - Efficacy
|
N/A | |
| Completed |
NCT02855762 -
Targeting the Microbiome to Improve Clinical Outcomes in Bipolar Disorder
|
N/A | |
| Recruiting |
NCT05915013 -
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
|
Phase 1 | |
| Recruiting |
NCT05206747 -
Ottawa Sunglasses at Night for Mania Study
|
N/A | |
| Completed |
NCT02513654 -
Pharmacokinetics, Safety and Tolerability of Repeat Dosing Lamotrigine in Healthy Chinese Subjects
|
Phase 1 | |
| Recruiting |
NCT06313918 -
Exercise Therapy in Mental Disorders-study
|
N/A | |
| Completed |
NCT02304432 -
Targeting a Genetic Mutation in Glycine Metabolism With D-cycloserine
|
Early Phase 1 | |
| Recruiting |
NCT06197048 -
Effect of Nutritional Counseling on Anthropometry and Biomarkers in Patients Diagnosed With Schizophrenia/Psychosis or Bipolar Affective Disorder
|
N/A | |
| Completed |
NCT03497663 -
VIA Family - Family Based Early Intervention Versus Treatment as Usual
|
N/A | |
| Completed |
NCT04284813 -
Families With Substance Use and Psychosis: A Pilot Study
|
N/A | |
| Completed |
NCT02212041 -
Electronic Cigarettes in Smokers With Mental Illness
|
N/A | |
| Recruiting |
NCT05030272 -
Comparing Two Behavioral Approaches to Quitting Smoking in Mental Health Settings
|
N/A | |
| Recruiting |
NCT04298450 -
ED to EPI: Using SMS to Improve the Transition From the Emergency Department to Early Psychosis Intervention
|
N/A | |
| Active, not recruiting |
NCT03641300 -
Efficacy of Convulsive Therapies for Bipolar Depression
|
N/A | |
| Not yet recruiting |
NCT04432116 -
Time and Virtual Reality in Schizophrenia and Bipolar Disorder
|
N/A | |
| Terminated |
NCT02893371 -
Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies
|
||
| Terminated |
NCT02909504 -
Gao NARASD Lithium Study
|
Phase 4 | |
| Completed |
NCT02970721 -
Use of Psychotropic Medications Among Pregnant Women With Bipolar Disorder
|
||
| Recruiting |
NCT03088657 -
Design and Methods of the Mood Disorder Cohort Research Consortium (MDCRC) Study
|
||
| Recruiting |
NCT02481245 -
BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study
|
Phase 2 |